• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Projects
  • Research Data
  • Organizations
  • Researchers
  • More
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. IL-9 sensitizes human Th2 cells to pro-inflammatory IL-18 signals in atopic dermatitis.
 

IL-9 sensitizes human Th2 cells to pro-inflammatory IL-18 signals in atopic dermatitis.

Options
  • Details
  • Files
BORIS DOI
10.48620/77449
Publisher DOI
10.1016/j.jaci.2024.10.027
PubMed ID
39521283
Description
Background
T helper 2 (Th2) cells crucially contribute to the pathogenesis of atopic dermatitis (AD) by secreting high levels of IL-13 and IL-22. Yet, the upstream regulators that activate Th2 cells in AD skin remain unclear. IL-18 is a putative upstream regulator of Th2 cells as it is implicated in AD pathogenesis and has the capacity to activate T cells.
Objective
To decipher the role of IL-18 in Th2 responses in blood and skin of AD patients.Methods
PBMCs and skin biopsies from AD patients and healthy donors were used. Functional assays were performed ex vivo using stimulation or blocking experiments. Analysis was performed using flow cytometry, bead-based multiplex assays, RT-qPCR, RNA-seq, western blotting, and spatial sequencing.
Results
IL-18Rα+ Th2 cells were enriched in blood and lesional skin of AD patients. Of all the cytokines for which Th2 cells express the receptor, only IL-9 was able to induce IL-18R via an IL-9R-JAK1/JAK3-STAT1 signaling pathway. Functionally, stimulation of circulating Th2 cells with IL-18 induced secretion of IL-13 and IL-22, an effect that was enhanced by co-stimulation with IL-9. Mechanistically, IL-18 induced Th2 cytokines via activation of IRAK4, NF-κB, and AP-1 signaling in Th2 cells, and neutralization of IL-18 inhibited these cytokines in cultured explants of AD skin lesions. Finally, IL-18 protein levels correlated positively with disease severity in lesional AD skin.
Conclusion
Our data identify a novel IL-9-IL-18 axis that contributes to Th2 responses in AD. Our findings suggest that both IL-9 and IL-18 could represent upstream targets for future treatment of AD.
Date of Publication
2025-02
Publication Type
Article
Subject(s)
600 - Technology::610 - Medicine & health
Keyword(s)
IL-9 receptor (IL-9R)
•
atopic dermatitis (AD)
•
interleukin-1 receptor-associated kinase 4 (IRAK4)
•
interleukin-18 (IL-18)
•
interleukin-18 receptor (IL-18R)
•
interleukin-9 (IL-9)
•
pathogenic Th2 cells (pTh2)
•
upstream regulator of Th2 cells
Language(s)
en
Contributor(s)
Schärli, Stefanie
Clinic of Dermatology
Graduate School for Cellular and Biomedical Sciences (GCB)
Luther, Fabianorcid-logo
Clinic of Dermatology
Di Domizio, Jeremy
Hillig, Christina
Radonjic-Hoesli, Susanne
Clinic of Dermatology
Thormann, Kathrin
Simon, Dagmar
Department for BioMedical Research, Forschungsgruppe Dermatologie
Clinic of Dermatology
Møller Rønnstad, Amalie Thorsti
Ruge, Iben Frier
Fritz, Blaine G
Bjarnsholt, Thomas
Vallone, Angela
Kezic, Sanja
Menden, Michael P
Roesner, Lennart M
Werfel, Thomas
Thyssen, Jacob P
Eyerich, Stefanie
Gilliet, Michel
Bertschi, Nicole L.
Clinic of Dermatology
Department for BioMedical Research, Forschungsgruppe Dermatologie
Schlapbach, Christoph
Department for BioMedical Research, Forschungsgruppe Dermatologie
Clinic of Dermatology
Additional Credits
Clinic of Dermatology
Department for BioMedical Research, Forschungsgruppe Dermatologie
Department for BioMedical Research (DBMR)
Graduate School for Cellular and Biomedical Sciences (GCB)
Series
Journal of Allergy and Clinical Immunology
Publisher
Elsevier
ISSN
1097-6825
0091-6749
Access(Rights)
open.access
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: ae9592 [15.12. 16:43]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo